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Proliferating cell nuclear antigen (PCNA) is involved in a wide range of functions in the nucleus.
However, a substantial amount of PCNA is also present in the cytoplasm, although their function
is unknown. Here we show, through Far-Western blotting andmass spectrometry, that PCNA is asso-
ciated with several cytoplasmic oncoproteins, including elongation factor, malate dehydrogenase,
and peptidyl-prolyl isomerase. Surprisingly, PCNA is also associated with six glycolytic enzymes that
are involved in the regulation of steps 4–9 in the glycolysis pathway.
Structured summary:
MINT-7995351: G3P (uniprotkb:P04406) and PCNA (uniprotkb:P12004) colocalize (MI:0403) by ﬂuores-
cence microscopy (MI:0416)
MINT-7995334: ENOA (uniprotkb:P06733) and PCNA (uniprotkb:P12004) colocalize (MI:0403) by ﬂuores-
cence microscopy (MI:0416)
MINT-7995368:
ALDOA (uniprotkb:P04075) and PCNA (uniprotkb:P12004) colocalize (MI:0403) by ﬂuorescence microscopy
(MI:0416)
MINT-7995141: G3P (uniprotkb:P04406) binds (MI:0407) to PCNA (uniprotkb:P12004) by far western blot-
ting (MI:0047)
MINT-7995182: ENOA (uniprotkb:P06733) binds (MI:0407) to PCNA (uniprotkb:P12004) by far western
blotting (MI:0047)
MINT-7995132: G3P (uniprotkb:P04406) physically interacts (MI:0915) with PCNA (uniprotkb:P12004) by
far western blotting (MI:0047)
MINT-7995228: PRDX6 (uniprotkb:P30041) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995220: CAH2 (uniprotkb:P00918) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995114: Triosephosphate isomerase (uniprotkb:P60174) binds (MI:0407) to PCNA (uni-
protkb:P12004) by far western blotting (MI:0047)
MINT-7995244: K2C7 (uniprotkb:P08729) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995252: ANXA2 (uniprotkb:P07355) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995122: Triosephosphate isomerase (uniprotkb:P60174) physically interacts (MI:0915) with PCNA
(uniprotkb:P12004) by far western blotting (MI:0047)
MINT-7995093: ALDOA (uniprotkb:P04075) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995148: PGK1 (uniprotkb:P00558) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)chemical Societies. Published by Elsevier B.V. All rights reserved.
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S.N. Naryzhny, H. Lee / FEBS Letters 584 (2010) 4292–4298 4293MINT-7995158: PGAM1 (uniprotkb:P18669) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995166: PGAM1 (uniprotkb:P18669) binds (MI:0407) to PCNA (uniprotkb:P12004) by far western
blotting (MI:0047)
MINT-7995105: ALDOA (uniprotkb:P04075) binds (MI:0407) to PCNA (uniprotkb:P12004) by far western
blotting (MI:0047)
MINT-7995260: PPIA (uniprotkb:P62937) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995173: ENOA (uniprotkb:P06733) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995268: EF1A (uniprotkb:P68104) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995236:MDHM (uniprotkb:P40926) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995189: RSSA (uniprotkb:P08865) physically interacts (MI:0915) with PCNA (uniprotkb:P12004)
by far western blotting (MI:0047)
MINT-7995282: PCNA (uniprotkb:P12004) physically interacts (MI:0915) with ALDOA (uniprotkb:P00883)
and G3P (uniprotkb:P46406) by anti bait coimmunoprecipitation (MI:0006).
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction 2.2. Far-Western blotting and image analysisProliferating cell nuclear antigen (PCNA) is central for many
essential cellular processes such as DNA replication and damage
repair, transcription, chromosome segregation, and cell-cycle pro-
gression [1–8]. All of these functions are carried out by PCNA in
the nucleus. Although a considerable amount of PCNA proteins
are also found in the cytoplasm, their function is currently
unknown [9].
Data obtained by several different techniques demonstrated
that PCNA molecules form a single or double homotrimer com-
plex that encircles the DNA ﬁber, and functions as a sliding clamp
for DNA polymerases and a docking station for many protein part-
ners [3,10–15]. A PCNA ring may bind to different protein part-
ners at different time and space to carry out speciﬁc tasks
[3,5,16,17].
We previously found that the level of PCNA is substantially
elevated in cancer cells, which is only notable difference be-
tween cancer and normal cells with respect to PCNA protein
[18]. Since PCNA–protein interactions may be affected by ele-
vated protein concentration at a given time and space, our ﬁnd-
ing raises the possibility that PCNA in cancer cells may interact
with certain proteins that do not normally interact with PCNA in
normal cells.
Cancer cells generally show an increase in glucose metabo-
lism, compared to normal cells [19–22]. This may be, in part,
due to the increase in the glucose trans-membrane transporta-
tion and concentration of glycolytic enzymes in cancer cells
[23–25]. The glucose metabolism may also be associated with
the ﬂux of metabolites through the cascade of 10 glycolytic en-
zymes. Here, we report that PCNA is associated with six glyco-
lytic enzymes involved in the regulation of steps 4–9 in the
glycolysis pathway, suggesting PCNA may coordinate at least part
of the glycolysis pathway in the cytoplasm. We have also found
that PCNA is associated with three known oncoproteins including
malate dehydrogenase, which is involved in the tricarboxylic acid
(TCA) cycle.
2. Materials and methods
2.1. One and two-dimensional gel electrophoresis
One- and two-dimensional gel electrophoresis (1-DE and 2-DE)
were carried out as described previously [18].Far-Western blot assays were carried out as described previ-
ously [26]. Brieﬂy, after proteins were transferred, the membrane
was rinsed once for 5 min in TBST (10 mM Tris–HCl, pH 7.9,
150 mM NaCl, 0.1% Tween 20), and 10 min in TBST with 5% BSA.
Proteins on the membrane were renatured by incubating the mem-
brane overnight at 4 C in AC buffer (10% glycerol, 100 mM NaCl,
20 mM Tris, pH 7.6, 0.5 mM EDTA, 0.1% Tween-20) containing 3%
BSA and 1 mM DTT. The membrane was then incubated for 4–7 h
at 4 C with 2.5 lg/ml PCNA in AC buffer containing 3% BSA and
1 mM DTT, followed by rinsing once in the same AC buffer
(15 min, 4 C) and once in TBST containing 3% BSA. The membrane
was incubated with primary antibody diluted in blocking solution
for 1 h at 4 C, washed twice (>15 min each) in Wash solution con-
taining TBS (0.8% (w/v) NaCl, 0.02% (w/v) KCl, 2 mM Tris, pH 7.6)
plus 0.1% [v/v] Tween-20. The membrane was incubated for
30 min at room temperature with a horseradish peroxidase-la-
beled secondary antibody (rabbit anti-mouse or goat anti-rabbit)
in Blocking buffer containing non-fat dry milk (5% [w/v]), Tween-
20 (0.1% [v/v] in TBS). The blot was washed three times in TBST
(>15 min each wash), incubated with ECL reagent (GE Healthcare),
and then exposed to an X-ray ﬁlm.
After 2-DE separation, gels were ﬁxed and SDS was washed off
by incubating the gels for 20 min in 25% isopropanol and 10% acetic
acid solution. Thewashing process was repeated at least oncemore.
The gels were stained overnight by incubating with 0.1% Coomassie
R350 in 40% methanol and 10% acetic acid, followed by destaining
in water for 1 h. The destaining step was repeated at least four
times. After scanning the gel, images were analyzed with Phoretix
2D (Nonlinear USA Inc., Durham, NC) and Delta2D software (Dec-
odon GmbH, Greifswald, Germany).2.3. MALDI-TOF
Peptide mass ﬁngerprint (PMF) analysis was carried out as de-
scribed previously [18] with some modiﬁcations. For detail, see
Supplementary data.2.4. Proteins and enzyme activities
Puriﬁed protein sources are listed in Supplementary data. GAP-
DH activity was examined using a KDalert kit according to the
Fig. 1. Identiﬁcation of PCNA-binding proteins in normal and cancer cells by 2-DE-Far-Western blotting. Protein extracts from HMEC (A and B) or MDA-MB468 (C and D) were
separated by 2-DE, transferred onto a membrane, renatured, and incubated with PCNA. PCNA-binding proteins were then detected with the PC10 monoclonal anti-PCNA
antibody. (B and D) Proteins separated by 2-DE were stained with Coomassie R350, protein spots corresponding to signals on the membrane (A and C) were identiﬁed, cut out,
and the identity of the proteins were determined by mass spectrometry (Supplementary Fig. S1).
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by determining absorbance at the 560 nm wavelength. Aldolase
activity was measured according to Pinto et al. [27] using a kit from
Caldon Biotech Inc. (Carlsbad, CA).
3. Results
3.1. Identiﬁcation of PCNA-binding proteins in normal and cancer cells
To gain insight into PCNA–protein interactions in normal and
cancer cells, we carried out 2-DE-Far-Western blot assays with ex-
tracts prepared from human mammary epithelial cells (HMEC)
normal (Fig. 1A and B) and MDA-MB468 cancer cells (Fig. 1C and
D). In the experiment, a set of two identical samples was subjected
to protein separation by 2-DE. Proteins in one of the two gels were
stained with Coomassie R350, and those of the other gel were
transferred onto a polyvinylidene diﬂuoride (PVDF) membrane.
The proteins on the membrane were renatured, and incubated
with puriﬁed PCNA proteins to allow PCNA–protein interactions
to occur. Subsequently, PCNA-binding proteins were detected with
an anti-PCNA antibody. By superimposing the X-ray ﬁlm (image),
the immunostained membrane and the Coomassie-stained gel,
PCNA and PCNA-associating proteins on the gel were identiﬁed,
and isolated. The identity of these proteins was determined by
PMF as shown in Supplementary Fig. 1.
Among more than 60 proteins detected by 2-DE-Far-Western
blotting, we chose to study 14 abundant PCNA-binding proteins
shown in Table 1. As expected from our previous work [18], the le-
vel of PCNA protein was much higher in MDA-MB468 than HMEC(compared Fig. 1A vs C). Annexin A2 (ANXA2), elongation factor 1
(EF1A), and glyceraldehyde-3-phosphate dehydrogenase (G3P)
were shown previously to interact with PCNA [28–32], and the rest
is reported here for the ﬁrst time. The levels of three gene products
involved in protein synthesis (RSSA, MDHM, and EF1A) were sub-
stantially higher in cancer than HMEC cells (Fig. 1A and C). In con-
trast, keratin type II cytoskeletal 7 (K2C7) and ANXA2, both of
which are relevant to the cytoskeleton integrity, were substantially
downregulated in cancer cells (Fig. 1).
Most interestingly, six of the fourteen PCNA-binding proteins
were glycolytic enzymes (Fig. 1 and Table 1). Since the ramiﬁcation
of this data could be very signiﬁcant, we further conﬁrmed the
association of these enzymes with PCNA by 1-DE-FarWestern blot-
ting using puriﬁed proteins. As shown in Fig. 2A and B, ﬁve of the
six enzymes were conﬁrmed to associate with puriﬁed PCNA (fruc-
tose-bisphosphate aldolase A, triosephosphate isomerase, glyceral-
dehyde-3-phosphate dehydrogenase, phosphoglycerate mutase 1,
and alpha-enolase). One PCNA-associating protein that we could
not conﬁrm by this experiment was phosphoglycerate kinase 1
(PGK 1) (Fig. 2, lane 7). However, this may be due to the fact that
we used puriﬁed yeast PGK1, which has only 60% of similarity to
human PGK1 at the level of amino acids. No puriﬁed mammalian
PGK1 is currently available. As expected, PCNA was not associated
with hexokinase-4, glucose-6-phosphate isomerase, 6-phospho-
fructokinase, pyruvate kinase, and lactate dehydrogenase. Overall,
this result conﬁrms the data obtained from the 2-DE-Far-Western
blotting (Fig. 1 and Table 1). Association of PCNA with fructose-
bisphosphate aldolase A (ALDOA) and G3P was also conﬁrmed by
co-immunoprecipitation (Fig. 2C and D).
Table 1
PCNA-associating proteins shown strong signals by Far-Western blotting.
Swiss Prot Protein name/synonyms Theoretical
pI/MW
Protein levels
(cancer vs
normal cells)
Function
ALDOA_HUMAN Fructose-bisphosphate aldolase A/muscle-type aldolase/lung cancer
antigen NY-LU-1
8.30/39420 No change Glycolysis, step 4
TPIS_HUMAN Triosephosphate isomerase/TIM/triose-phosphate isomerase 6.45/26669 No change Glycolysis, step 5
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase/GAPDH 8.57/36053 No change Glycolysis, step 6
PGK1_HUMAN Phosphoglycerate kinase 1/primer recognition protein 2/PRP 2/cell
migration-inducing gene 10 protein
8.30/44615 No change Glycolysis, step 7
PGAM1_HUMAN Phosphoglycerate mutase 1/phosphoglycerate mutase isozyme B/
PGAM-B/BPG-dependent PGAM 1
6.67/28804 No change Glycolysis, step 8
ENOA_HUMAN Alpha-enolase/2-phospho-D-glycerate hydro-lyase/non-neural
enolase/NNE/enolase 1/phosphopyruvate hydratase/C-myc promoter-
binding protein/MBP-1/MPB-1/plasminogen-binding protein
7.01/47169 No change Glycolysis, step 9
RSSA_HUMAN 40S ribosomal protein SA/laminin receptor 1/LamR/37/67 kDa laminin
receptor/LRP/LR/laminin-binding protein precursor p40/LBP/p40/
37 kDa laminin receptor precursor/37LRP 67 kDa laminin receptor/
67LR/colon carcinoma laminin-binding protein/NEM/1CHD4/
multidrug resistance-associated protein MGr1-Ag
4.79/32854 Up in cancer Ribosome/cell surface
receptor/signaling transduction
CAH2_HUMAN Carbonic anhydrase 2/carbonic anhydrase II/CA-II/carbonate
dehydratase II/carbonic anhydrase C/CAC
6.87/29246 Down in cancer Reversible hydration of carbon dioxide
PRDX6_HUMAN Peroxiredoxin-6/antioxidant protein 2/1-cys peroxiredoxin/1-Cys PRX/
acidic calcium-independent phospholipase A2/aiPLA2/non-selenium
glutathione peroxidase/NSGPx/24 kDa protein. Liver 2D PAGE spot 40/
red blood cells PAGE spot 12
6.00/25034 Up in cancer Redox regulation
MDHM_HUMAN Malate dehydrogenase, mitochondrial precursor 8.92/35503 Up in cancer Tricarboxylic acid cycle
K2C7_HUMAN Keratin, type II cytoskeletal 7/cytokeratin-7/(CK-7/keratin-7/K7/
sarcolectin Speciﬁc marker for pancreatic cancer
5.50/51418 Down in cancer Cytoskeleton/signaling transduction
ANXA2_HUMAN Annexin A2/annexin-2/annexin II/lipocortin II/calpactin I heavy chain/
chromobindin-8/p36/protein I/placental anticoagulant protein IV/PAP-
IV
7.57/38604 Down in cancer Membrane/cytoskeleton
PPIA_HUMAN Peptidyl-prolyl cis–trans isomerase A/PPIase A/rotamase A/cyclophilin
A/cyclosporin A-binding protein
7.68/18012 Up in cancer Folding of proteins
EF1A_HUMAN Elongation factor 1/eEF1A/elongation factor Tu/EF-Tu 9.10/50140 Up in cancer Translation/cytoskeleton
Fig. 2. An in vitro assay showed that PCNA interacts with proteins involved in the glycolysis pathway. Two sets of puriﬁed proteins were separated by SDS–PAGE, and then
transferred onto membranes. (A) The ﬁrst set of protein samples was incubated with puriﬁed PCNA proteins, followed by Western blotting with PC10. (B) The second set was
stained with Coomassie R350. Protein samples are follows: hexokinase-4 (lane 1), glucose-6-phosphate isomerase (lane 2), 6-phosphofructokinase (lane 3), fructose-
bisphosphate aldolase A (lane 4), triosephosphate isomerase (lane 5), glyceraldehyde-3-phosphate dehydrogenase (lane 6), phosphoglycerate kinase 1 (lane 7),
phosphoglycerate mutase 1 (lane 8), alpha-enolase (lane 9), pyruvate kinase (lane 10), and lactate dehydrogenase (lane 11). (C) Puriﬁed human PCNA (10 mg/ml), rabbit
Aldolase (100 mg/ml; ALDOA), and rabbit GAPDH (100 mg/ml; G3P) were mixed together in 200 ml of PBS, incubated 1 h at 4 C, followed by immunoprecipitation with PC10
conjugated to agarose beads (PC10-AC). The immunoprecipitate was then separated by 2-DE, followed by staining with Coomassie R350. (D) The same procedure was carried
out as per legend to panel C; however, 50 mg/ml BSA was used in the place of PCNA for immunoprecipitation.
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Fig. 3. A subpopulation of PCNA proteins was co-localized with enolase (ENOA), G3P, and ALDOA. (A) MDA-MB468 and184B5 cells were immunostained with a mouse anti-
PCNA PC10 antibody, followed by staining with rhodamin-labeled chicken anti-mouse IgG. The cells were also stained with a rabbit anti-enolase A antibody, followed by
staining with FITC-labeled goat anti-rabbit IgG. White arrows show the areas of co-localization of enolase with cytoplasmic PCNA. Green arrows show the area where the
presence of alpha-enolase is pronounced but PCNA is largely absent. The inner box in the merged image is an enlarged image of the cell at the bottom right. (B) HEK 293 cells
stably expressing GFP-PCNA were stained with a mouse anti-G3P antibody (secondary antibody was rhodamin-labeled chicken anti-mouse IgG), or with a rabbit anti-aldolase
antibody (secondary antibody was rhodamin-labeled donkey anti-goat IgG; sc-2094). Arrows show co-localization of PCNA with G3P or ALDOA. PCNA denotes GFP-PCNA
fusion protein.
Fig. 4. Glycolytic activities were modestly stimulated by PCNA. (A) An Aldolase reaction was carried out without (0) or with PCNA (1–3). The samples 1–3 included 2.5 lg/ml,
5 lg/ml, and 10 lg/ml of PCNA, respectively. The aldolase activity is expressed in an arbitrary unit. Mean values of three independent experiments are present. Error bars are
standard errors. (B) PCNA enhanced the GAPDH activity. The GAPDH activity was measured with extracts prepared from HEK 293 and stably transfected HEK 293 cells with
GFP-PCNA. Mean values of two experiments are present. (C) Both HEK 293 and HEK 293 expressing GFP-PCNA contained a similar amount of G3P protein, and slightly higher
amount of total PCNA (endogenous PCNA plus the exogenous GFP-PCNA). Lanes 1 and 3, extract from HEK 293 cells; lanes 2 and 3, extracts from HEK 293 expressing GFP-
PCNA; lanes 1 and 2, stained with Coomassie R350; and lanes 3 and 4, stained with an anti-G3P antibody and then an anti-PCNA antibody.
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S.N. Naryzhny, H. Lee / FEBS Letters 584 (2010) 4292–4298 42973.2. Co-localization of glycolytic enzymes and a PCNA subpopulation
in the cells
Since essentially all of the 14 PCNA-binding enzymes were cyto-
plasmic proteins (Table 1), we examined if a subpopulation of
PCNA co-localized with these enzymes. Data shown in Fig. 3A
demonstrates that a subpopulation of PCNA is co-localized with al-
pha-enolase in both the MDA-MB468 and 184B5 cells (white ar-
rows). One notable difference between MDA-MB468 cancer and
184B5 non-cancer cells was that enolase A was more clustered
around the perinuclear membrane region in the cancer cells, but
more spread throughout the cytoplasm in the 184B5 cells. Further-
more, the nuclear and cytoplasmic PCNA proteins were separated
by strong presence of an enolase subpopulation (green arrows) in
MDA-MB468 but not 184B5 cells. This observation raises the
possibility that PCNA–protein interactions can be substantially dif-
ferent between cancer and non-cancer cells. However, the signiﬁ-
cance of this data is currently unknown.
To gain further insight into the localization of cytoplasmic PCNA
and glycolytic enzymes, we examined subcellular localization of
PCNA, G3P and ALDOA in the HEK 293 cells stably transfected with
a GFP-PCNA construct (Fig. 3B). We found that cytoplasmic PCNA
was largely co-localized with G3P and ALDOA proteins (Fig. 3B).
3.3. PCNA stimulates the activity of glycolytic enzymes
Next, we measured the aldolase activity in a varying amount of
puriﬁed PCNA proteins. As shown in Fig. 4A, the aldolase activity
steadily increased as the amount of PCNA increased in the reaction
solution. Similarly, glyceraldehyde-3-phosphate dehydrogenase
activity was higher in the cell extracts prepared from HEK 293 cells
stably transfected with GFP-PCNA than parental HEK 293 cells,
although the levels of G3P proteins were similar for both the cell
lines (Fig. 4C).4. Discussion
Amino acid sequence analysis suggested that none of the 14
PCNA-binding proteins in the cytoplasm contained the canonical
PCNA interacting protein (PIP) box, which interacts with the
hydrophobic pocket in the PCNA Interdomain loop [12,33,34].
However, ﬁve of them (ALDOA, ANXA2, EF1A, PGK1, and MDHM)
contain sequences similar to the KA box, KA(A/L/I)(A/L/Q)XX(L/V),
which binds to the PCNA C-terminal tail region [8]. This is interest-
ing since this data may indicate that the interactions between
PCNA and its partners in the cytoplasm could be slightly different
from those in the nucleus. The other nine PCNA-associating pro-
teins do not contain either consensus motif. However, it should
be noted that many PCNA-binding proteins do not contain either
PIP or KA box [8]. Furthermore, proteins with low afﬁnity for PCNA
can become interactive with PCNA when levels of both PCNA and
its potential binding partners are high.
We have recently found that PCNA contains a nuclear localiza-
tion sequence (NLS) within the amino acid 101–120 segment [35],
and its nuclear import appears to be mediated by importin b as
PCNA binds to importin-b, but not importin-a [36]. These data sug-
gest that cells have an active mechanism for the cytoplasmic local-
ization of PCNA, which is yet to be elucidated.
Annexin A2 was quite abundant in HMEC but barely detectable
in MDA-MB468 cells (Fig. 1A and C). Annexin A2 plays an impor-
tant role in cell membrane physiology, and the deregulation of this
protein is often associated with cancer [37]. The binding of PCNA to
the annexin A2 ‘‘membrane protein” was very surprising, since the
localization of PCNA at the plasma membrane has never been
reported. Nevertheless, it should be noted that the association ofannexin A2 and PCNA was also found by another group [29]. Car-
bonic anhydrase, which catalyzes reversible hydration of carbon
dioxide, is associated with diverse pathological conditions; thus,
it has been a target for drug developments for several human dis-
eases, including glaucoma and cancer [38,39]. These data together
with our current ﬁnding raise the possibility that PCNA may be
involved in (preventing) pathological development by binding
and modulating carbonic anhydrase. Keratins are well-known
intermediate ﬁlament proteins. Like actin ﬁlaments, keratins are
ﬂexible but provide a ﬁrm cell skeleton. The type II cytokeratin is
speciﬁcally expressed in the epithelial lining of the internal organ
cavities, gland ducts, and blood vessels. In addition, the K2C7
monomer sarcolecti functions as a tissue growth factor in balance
with interferons; thus, it may be involved in the regulation of cell
growth and differentiation [40].
The elongation factor 1 was the most highly expressed protein
among the fourteen PCNA-associating proteins in cancer cells,
compared to HMEC cells. This observation is consistent with the
previous report that EF1A may function as an oncoprotein
[41,42]. In addition to the elevated expression, EF1A proteins also
appear to be extensively modiﬁed in cancer cells, as they are found
at a wide range of different pI positions (Fig. 1C). Three other
PCNA-binding proteins upregulated in cancer cells are all relevant
to cancer development and progress. Peptidyl-prolyl cis–trans
isomerase frequently over-expresses in many cancer tissues
[43–46]. The level of mitochondrial malate dehydrogenase is often
elevated in the human breast cancer tissue [47]. Peroxiredoxin-6
over-expression may be involved in metastatic progression of
breast tumors [48]. Together, these data suggest that PCNA may
be involved in the regulation of oncogenic development and
progress.
The most surprising result was the ﬁnding that PCNA is associ-
ated with six enzymes that are involved in the six consecutive
steps of the glycolysis pathway (steps 4–9). Although the overall
levels of these proteins are similar in both cancer and normal cells
(Table 1), the patterns of post-translational modiﬁcations appear to
be different for phosphoglycerate kinase 1 and glyceraldehyde-
3-phosphate dehydrogenase (Fig. 1). It is possible that these
post-translational modiﬁcations may be part of the regulation
mechanism of PCNA–protein interactions (e.g., an increase in afﬁn-
ity for PCNA). Since glycolysis occurs in the cytoplasm, our data
suggest that PCNA has important biological functions in the cyto-
plasm. In addition to glycolysis, PCNA may also be involved in
the regulation of the energy generating system in the mitochondria
as it binds to malate dehydrogenase (Fig. 1 and Table 1). Our data
also support the notion that cytoplasmic PCNA is involved in the
regulation of cytoskeleton integrity and other cellular signaling
pathway through binding to cytoplasmic and membrane proteins,
including annexin A2, sarcolectin, elongation factor 1, peptidyl-
prolyl cis–trans isomerise, or 40S ribosomal proteins.
A PCNA toroidal complex may be a vehicle that can simulta-
neously and successively interacting with different enzymes at
different stages of a signaling or metabolic pathway, and thus facil-
itate signal or product-substrate transfer to the next step. This
model is consistent with our observation that PCNA could stimu-
late aldolase activities when added to the reaction system contain-
ing aldolase, triosephosphate isomerase, and GAPDH representing
glycolysis steps 4–6 (Fig. 4A). Similarly, the GAPDH activity was
moderately higher when it was measured with cell extracts pre-
pared from HEK 293 expressing high level of cytoplasmic PCNA
than parental HEK 293 (Fig. 4B).
In summary, our data suggests that cytoplasmic PCNA may be
involved in the regulation of oncogenesis, the glycolysis pathway,
and cytoskeleton integrity. Further studies on the function of cyto-
plasmic PCNA are likely to provide signiﬁcant new insights into the
mechanism of pathological development in human cells.
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